C. Steven Ernest - Concepedia

Author

C. Steven Ernest

Also Known As

B. Augendre-Ferrante, C Ernest, C S Ernest, C Steven Ernest, C. Ernest, C. S. Ernest, C. S. Ernest II, C. Steven Ernest, C. Steven Ernest II, C.S. ERNEST

Publications

2.8K

Citations

H-Index

Concepts

All Affiliations

Eli Lilly (United States)Daiichi Sankyo (United States)Eli Lilly (United Kingdom)Eli Lilly (Singapore)Profil Institute for Metabolic Research

About

C. Steven Ernest is an author at Eli Lilly (United States) specializing in medicine, pharmacotherapy, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	9	9	1.1K
2	Health Sciences	3	3	183
3	Education	1	1	15
4	Natural Sciences	1	1	51
5	Allergy	1	1	83

C. Steven Ernest

Publications

2.5K

Citations

H-Index

Page 1

	Year	Citations
Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel John T. Brandt, Sandra Close, Stephen J. Iturria, Journal of Thrombosis and Haemostasis MedicineGeneticsPharmacodynamic ResponseCommon PolymorphismsPharmacogenomics	2007	726
Cytochrome P450 3A Inhibition by Ketoconazole Affects Prasugrel and Clopidogrel Pharmacokinetics and Pharmacodynamics Differently Nazar Farid, Christopher D. Payne, D. S. Small, Clinical Pharmacology & Therapeutics	2007	321
Mechanism-Based Inactivation of CYP3A by HIV Protease Inhibitors C. Steven Ernest, Stephen D. Hall, David Jones Journal of Pharmacology and Experimental Therapeutics	2005	250
Increased Active Metabolite Formation Explains the Greater Platelet Inhibition With Prasugrel Compared to High-dose Clopidogrel Christopher D. Payne, Ying Grace Li, David S. Small, Journal of Cardiovascular Pharmacology	2007	167
Effect of Potent CYP2D6 Inhibition by Paroxetine on Atomoxetine Pharmacokinetics Donna J. Belle, C. Steven Ernest, John‐Michael Sauer, The Journal of Clinical Pharmacology	2002	93
Effect of Atorvastatin on the Pharmacokinetics and Pharmacodynamics of Prasugrel and Clopidogrel in Healthy Subjects Nagy A. Farid, David S. Small, Christopher D. Payne, Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy	2008	87
Population Pharmacokinetic Analyses to Evaluate the Influence of Intrinsic and Extrinsic Factors on Exposure of Prasugrel Active Metabolite in TRITON‐TIMI 38 Rebecca E. Wrishko, C. Steven Ernest, David S. Small, The Journal of Clinical Pharmacology Pras-am ExposuresPharmacotherapyPhysiologically-based Pharmacokinetic ModelingLogistic AnalysisPharmacodynamic Modeling	2009	83
Dose Response of Inhaled Dry-Powder Insulin and Dose Equivalence to Subcutaneous Insulin Lispro Klaus Rave, Leszek Nosek, Amparo de la Peña, Diabetes Care	2005	75
STOCHASTIC PREDICTION OF CYP3A-MEDIATED INHIBITION OF MIDAZOLAM CLEARANCE BY KETOCONAZOLE Jenny Y. Chien, Aroonrut Lucksiri, C. Steven Ernest, Drug Metabolism and Disposition	2006	74
Prasugrel pharmacokinetics and pharmacodynamics in subjects with moderate renal impairment and end-stage renal disease D. S. Small, Rebecca E. Wrishko, C. Steven Ernest, Journal of Clinical Pharmacy and Therapeutics	2009	72

Page 1